InfosurhoyResearchers advance CRISPR-based diagnostic tool, develop …InfosurhoyThe SHERLOCK team developed a simple paper strip to display test results for a single genetic signature, borrowing from the visual cues common in pregnancy tests. After di… Continue reading
Infosurhoy |
Researchers advance CRISPR-based diagnostic tool, develop miniature paper test
Infosurhoy At the core of SHERLOCK’s success is a CRISPR-associated protein called Cas13, which can be programmed to bind to a specific piece of RNA. Cas13’s target can be any genetic sequence, including viral genomes, genes that confer antibiotic resistance in … |
Reuters |
AstraZeneca’s immunotherapy drug wins key lung cancer approval
Reuters LONDON (Reuters) – AstraZeneca’s immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. FILE PHOTO: A sign is … Imfinzi Approved to Reduce Risk of NSCLC ProgressionRegulatory Focus |
Regulatory Focus |
Imfinzi Approved to Reduce Risk of NSCLC Progression
Regulatory Focus AstraZeneca’s immunotherapy Imfinzi (durvalumab) is now approved to reduce the risk of non-small-cell lung cancer (NSCLC) progression in patients with stage III disease whose tumors cannot be surgically removed after treatment with chemotherapy and … US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCERPR Newswire (press release) |
Reuters |
US FDA approves AstraZeneca’s immunotherapy for lung cancer
Reuters (Reuters) – The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc’s, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can’t be surgically removed. FILE PHOTO: A sign is seen at … |
|
US FDA approves AstraZeneca’s immunotherapy for lung cancer
Reuters (Reuters) – The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc’s, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can’t be surgically removed. FILE PHOTO: A sign is seen at … |